Hawthorne Effect, a specialist in technology-enabled mobile clinical research, announced the appointment of Josh Rose as new CEO.
The organisation describes Rose as a clinical trial industry veteran with over 14 years of executive leadership experience with companies such as IQVIA, CVS Health and others.
“I’ve always been attracted to companies that have a unique approach to solving significant industry challenges,” said Rose. “Driving greater patient access and participation in clinical trials is one of the most pressing challenges for pharma sponsors. Hawthorne Effect’s pioneering approach to rapidly enabling study visits in the patient’s home at attractive unit economics, eliminates the barrier for greater adoption of mobile visits in hybrid or any clinical trial.”
Hawthorne Effect has also strengthened its board of directors with three new appointments who together bring over 50 years of clinical trials, biotechnology and patient services experience. New directors include Jon DiVincenzo, EVP & president, Central Laboratories Services and International, Labcorp, Tony Clapsis, former SVP at CVS Health, and Ingo Chakravarty, operating partner at Northpond Ventures and former CEO of Mesa (sold to Fisher Scientific).
“Transforming clinical trials is not about flashy tech and buzz words. It’s brass-tacks operational delivery with practical solutions that work,” said Clapsis. “With the industry’s largest network of GCP trained independent clinicians, enabled by a novel tech approach, Hawthorne Effect rapidly matches and schedules mobile trial visits anywhere.” New members join current board members Jodi Akin (Hawthorn Effect founder) and Lucy Coassin.
Labcorp and Hawthorne Effect recently announced a strategic partnership to increase patient diversity, decrease site burden, and accelerate enrolment and clinical study timelines.
“At Labcorp, we are committed to making life-saving clinical trials more accessible, diverse and inclusive to all communities,” said DiVincenzo. “Through this collaboration, we look forward to combining Labcorp’s global laboratory network and logistics capabilities with Hawthorne Effect’s digital platform to advance our decentralized clinical trial capabilities, increase clinical trial accessibility and diversity, and bring greater value to patients, their physicians and our sponsors.”
Among the clinical trials Hawthorne Effect is partnering on is the PREVUE VALVE study, which is led by the Cardiovascular Research Foundation (CRF), and seeks to quantify the true prevalence of valvular heart disease within the USA. Use of cloud-based software has markedly boosted the diversity of the trial population, with the trial currently reaching over three times the average for target demographics compared to other research, organisers reported in October 2023.
